Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Indivior Pharmaceuticals (INDV) EBT Margin (2022 - 2025)

Historic EBT Margin for Indivior Pharmaceuticals (INDV) over the last 4 years, with Q3 2025 value amounting to 11.78%.

  • Indivior Pharmaceuticals' EBT Margin rose 20100.0% to 11.78% in Q3 2025 from the same period last year, while for Sep 2025 it was 16.61%, marking a year-over-year increase of 129800.0%. This contributed to the annual value of 1.68% for FY2024, which is 149500.0% up from last year.
  • Per Indivior Pharmaceuticals' latest filing, its EBT Margin stood at 11.78% for Q3 2025, which was up 20100.0% from 20.53% recorded in Q2 2025.
  • In the past 5 years, Indivior Pharmaceuticals' EBT Margin ranged from a high of 26.24% in Q2 2022 and a low of 106.22% during Q4 2022
  • In the last 4 years, Indivior Pharmaceuticals' EBT Margin had a median value of 20.67% in 2023 and averaged 0.35%.
  • The largest annual percentage gain for Indivior Pharmaceuticals' EBT Margin in the last 5 years was 1270400bps (2023), contrasted with its biggest fall of -900700bps (2023).
  • Indivior Pharmaceuticals' EBT Margin (Quarter) stood at 106.22% in 2022, then surged by 120bps to 20.82% in 2023, then plummeted by -39bps to 12.75% in 2024, then fell by -8bps to 11.78% in 2025.
  • Its EBT Margin stands at 11.78% for Q3 2025, versus 20.53% for Q2 2025 and 22.18% for Q1 2025.